Labuxtinib

CAS No. 1426449-01-5

Labuxtinib( —— )

Catalog No. M37250 CAS No. 1426449-01-5

Labutinib is a selective inhibitor of the c-kit tyrosine kinase .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 373 In Stock
5MG 337 In Stock
10MG 541 In Stock
25MG 1074 In Stock
50MG 1516 In Stock
100MG 2037 In Stock
200MG 2744 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Labuxtinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Labutinib is a selective inhibitor of the c-kit tyrosine kinase .
  • Description
    Labuxtinib is c-kit tyrosine kinase inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR | c-Kit
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1426449-01-5
  • Formula Weight
    377.37
  • Molecular Formula
    C20H16FN5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (331.24 mM; Ultrasonic )
  • SMILES
    C(NC1=CC(=CC=C1C)C=2N=C(ON2)[C@@H]3[C@@H](F)C3)(=O)C=4N5C(=NC4)C=CC=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yeh Vince, et al. Imidazopyridine compounds and compositions as c-kit kinase inhibitors and their preparation. World Intellectual Property Organization, WO2013033070 A1. 2013-03-07.
molnova catalog
related products
  • Sunvozertinib

    Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2, and mutant epidermal growth factor.

  • Rezivertinib

    Rezivertinib (BPI-7711) is an orally available, selective and potent inhibitor of tyrosine kinase (EGFR) with antitumor activity for central nervous system disorders.

  • XL-647

    XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.